Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Refractory and relapsing sarcoma and high-risk neuroblastoma show poor prognoses. Monocyte-derived dendritic cell anticancer vaccine could extend the treatment modalities in these patients. Pharmacotherapy prior to mononuclear cell harvest may influence the quality of manufactured dendritic cell product. |
| Related projects: |